Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa. The SHARPS randomized clinical trial.

The effect of perioperative adalimumab continued for ten weeks after radical surgery (wide excision followed by secondary intention healing) was examined in this study that included 206 patients. A good clinical response was more common with adalimumab therapy: 48 versus 34 per cent, P=0.049.

Comment: Some possible hope for patients with a difficult disease to manage.